Catalog No.
FHG17623
Species reactivity
Human
Host species
Mouse
Isotype
IgG1, kappa
Clonality
Monoclonal
Conjugation
APC
Applications
FCM
Target
Leukocyte surface antigen CD47, CD47, Antigenic surface determinant protein OA3, IAP, Integrin-associated protein, Protein MER6, MER6
Concentration
0.5 mg/ml
Endotoxin level
Please contact with the lab for this information.
Accession
Q08722
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.
Stability and Storage
Store at 4°C for 12 months. Protect from light. Do not freeze.
Clone ID
B6H12
Note
For research use only.
Blockade of TSP-1/CD47 signal axis promotes donor hematopoietic engraftment by improving SEC/MK niche function., PMID:40060904
A review of antibody-based immunotherapy clinical trials for adult acute myeloid leukemia (AML): monoclonal antibodies (mAbs) and beyond., PMID:40069930
Deciphering the IgG Idiotype Network Through Proteomic Analysis of Potential Targets in SARS-CoV-2-Induced Immune Responses., PMID:40077865
Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy., PMID:40078999
Development of a Novel Bifunctional Anti-CD47 Fusion Protein with Improved Efficacy and a Favorable Safety Profile., PMID:40084615
CD47 peptide-cloaked lipid nanoparticles promote cell-specific mRNA delivery., PMID:40087866
Regulating islet stress responses through CD47 activation., PMID:40133488
Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy., PMID:40136470
Programmable engineered bacteria as sustained-releasing antibody factory in situ for enhancing tumor immune checkpoint therapy., PMID:40138400
A Phase 1b/2 Study of the Anti-CD47 Antibody Magrolimab with Cetuximab in Patients with Colorectal Cancer and Other Solid Tumors., PMID:40140179
Dual blockade of GSTK1 and CD47 improves macrophage-mediated phagocytosis on cancer cells., PMID:40147800
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)., PMID:40175391
Generation and characterization of 7DC-DM1: a non-cleavable CD47-targeting antibody-drug conjugates with antitumor effects., PMID:40187444
High-Throughput Screening on Primary Tumor-Associated Microglia and Macrophages Identifies HDAC Inhibitors as Enhancers of Phagocytosis and Potent Partners for Immunotherapy in Glioblastoma., PMID:40196519
Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis., PMID:40198272
An oncolytic vaccinia virus expressing anti-CD47 nanobody exerts enhanced antitumor activity by mediating innate and adaptive immune cell infiltration and activation in the lymphoma tumor microenvironment., PMID:40207734
Molecular and Immunometabolic Landscape of Erythrophagocytosis-induced Ferroptosis., PMID:40231500
The "don't eat me" signal CD47 is associated with microglial phagocytosis defects and autism-like behaviors in 16p11.2 deletion mice., PMID:40238451
Nanobody Engineered and Photosensitiser Loaded Bacterial Outer Membrane Vesicles Potentiate Antitumour Immunity and Immunotherapy., PMID:40240911
Successful targeting of multidrug-resistant tumors with bispecific antibodies., PMID:40248904
Inhibition of polymorphonuclear cells averts cytotoxicity against hypoimmune cells in xenotransplantation., PMID:40251154
CD47 regulates antigen modulation and red blood cell clearance following an incompatible transfusion., PMID:40255405
CD47-blocking antibody confers metabolic benefits against obesity., PMID:40267910
Multi-Omics Analysis of the Immune Effect of the Engineered Exosome Drug Delivery System in Inducing Macrophage Apoptosis., PMID:40284489
Engineered Bacterial Outer Membrane Vesicles Hitchhiking on Neutrophils for Antibody Drug Delivery to Enhance Postoperative Immune Checkpoint Therapy., PMID:40287972
N-deglycosylation targeting chimera (DGlyTAC): a strategy for immune checkpoint proteins inactivation by specifically removing N-glycan., PMID:40289109
Oncolytic adenovirus H101 enhances the anti-tumor effects of PD-1 blockade via CD47 downregulation in tumor cells., PMID:40296909
CAR macrophages with built-In CD47 blocker combat tumor antigen heterogeneity and activate T cells via cross-presentation., PMID:40307254
TSP-1-CD47-integrin α4β1 axis drives T cell infiltration and synovial inflammation in rheumatoid arthritis., PMID:40308591
Nanobody-Based PET Imaging of CD47 Expression in Thyroid Carcinoma., PMID:40326602
Augmented CD47 expression impairs alloreactive T-cell clearance after allo-HCT., PMID:40332470
Refolding of the recombinant IgV domain of CD47 from E. coli for NMR studies., PMID:40334763
Virtual Clinical Trial Reveals Significant Clinical Potential of Targeting Tumor-Associated Macrophages and Microglia to Treat Glioblastoma., PMID:40347051
Dual targeting of ENPP3 and SIRPα with a bispecific antibody enhances macrophage-mediated immunity in renal cell carcinoma., PMID:40349459
The Efficacy of Targeted Monoclonal IgA Antibodies Against Pancreatic Ductal Adenocarcinoma., PMID:40358156
Magrolimab Therapy in Conjunction with Conventional Chemotherapeutics Slows Disease Progression in Pediatric Acute Myeloid Leukemia Patient-Derived Xenograft Models., PMID:40361435
Immunotherapy of endometrial cancer via CD47 blockade-mediated macrophage phagocytosis., PMID:40371397
CD47 expression in classic follicular lymphoma is associated with event-free survival., PMID:40374148
Tumor-derived exosomal CCT6A serves as a matchmaker introducing chemokines to tumor-associated macrophages in pancreatic ductal adenocarcinoma., PMID:40374617
USP2 inhibition unleashes CD47-restrained phagocytosis and enhances anti-tumor immunity., PMID:40379682
Targeted CD47 checkpoint blockade using a mesothelin-directed antibody construct for enhanced solid tumor-specific immunotherapy., PMID:40402266
A human antibody specific for SIRPα reprograms macrophages and promotes antibody mediated anti-cancer activity., PMID:40408355
The cytotoxic effect of quercetin-induced apoptosis on lung metastatic cells from giant cell tumor of bone., PMID:40418557
CDC34 suppresses macrophage phagocytic activity and predicts poor response to immune checkpoint inhibitor in cancers., PMID:40419082
CD99: A Key Regulator in Immune Response and Tumor Microenvironment., PMID:40427525
Monoclonal Antibodies Against Myeloid Leukemia Cells: Current Knowledge and Future Directions., PMID:40429716
Efferocytosis and its role in rheumatic diseases., PMID:40452369
Dual blockade of TNFR2 and CD47 reshape tumor immune microenvironment and improve antitumor effects in colorectal cancer., PMID:40450521
Nanoparticle-formulated mRNA encoding engineered multivalent SIRPα-Fc fusion proteins shows robust anti-cancer activity in preclinical models., PMID:40487351
PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance., PMID:40512837
For research use only. Not for human or drug use.
